Abstracts tagged "systemic sclerosis and tocilizumab"

Abstract Number: 1740 • 2018 ACR/ARHP Annual Meeting
Effectiveness and Safety of Tocilizumab for the Treatment of Refractory Systemic Sclerosis Associated Interstitial Lung Disease: A Case Series
Judit Lluch¹, Ivan Castellvi², J Alegre³, Pablo Juárez¹, Joan Miquel Nolla¹ and Francisco Javier Narváez⁴, ¹Rheumatology, Hospital Universitario de Bellvitge, Barcelona, Spain, ²Rheumatology, Hospital Santa Creu i San Pau, Barcelona, Spain, ³Rheumatology, Hospital Universitario Doctor Peset. Valencia. Spain, Valencia, Spain, ⁴Rheumatology Department, Hospital Universitario de Bellvitge, Idibell, Barcelona, Spain
Background/Purpose: To evaluate the efficacy and safety of TCZ as as a rescue therapy in patients with refractory scleroderma-associated interstitial lung disease (SSc-ILD). Methods: We…
Abstract Number: 126 • 2018 ACR/ARHP Annual Meeting
Direct Interaction between Autoreactive B Cells and Endothelial Colony Forming Cells Induces Cytokine Production from B Cells through B Cell Receptor and IL-6-JAK2-STAT3 Signaling Pathway, Suppressing Proliferation of Endothelial Colony Forming Cells in Systemic Sclerosis
Takemichi Fukasawa¹, Ayumi Yoshizaki¹, Satoshi Ebata¹, Kouki Nakamura¹, Yoshihide Asano¹, Yutaka Kazoe², Kazuma Mawatari², Takehiko Kitamori² and Shinichi Sato¹, ¹Department of Dermatology, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan, ²Department of Applied Chemistry, Graduate School of Engineering, The University of Tokyo, Tokyo, Japan
Background/Purpose: Systemic sclerosis (SSc) is a connective tissue disorder that is characterized by fibrosis and vascular damage in the skin and other visceral organs, with…
Abstract Number: 969 • 2016 ACR/ARHP Annual Meeting
Safety and Efficacy of Subcutaneous Tocilizumab in Early Systemic Sclerosis: Results from the Open-Label Period of a Phase 2 Randomized, Controlled Trial
Dinesh Khanna¹, Christopher Denton², Helen Spotswood³, Angelika Jahreis⁴, Jacob M. van Laar⁵, Laura Burke⁶, Celia J. F. Lin⁴, Janet E. Pope⁷, Yannick Allanore⁸, Ulf Müller-Ladner⁹, Jeffrey Siegel⁶, Daniel E. Furst¹⁰ and faSScinate Clinical Trial Investigators, ¹University of Michigan, Ann Arbor, MI, ²Division of Medicine, Centre for Rheumatology and Connective Tissue Disease, University College London, London, United Kingdom, ³Roche Products Ltd., Welwyn Garden City, CA, United Kingdom, ⁴Genentech, South San Francisco, CA, ⁵University Medical Center Utrecht, Utrecht, Netherlands, ⁶Roche Products Ltd., Welwyn Garden City, United Kingdom, ⁷University of Western Ontario, St Joseph's Health Care, London, ON, Canada, ⁸Rheumatology, Paris Descartes University, Paris, France, ⁹Justus-Liebig-University Giessen, Department of Internal Medicine and Rheumatology, Kerckhoff-Klinik, Bad Nauheim, Germany, Bad-Nauheim, Germany, ¹⁰University of California, Los Angeles, Los Angeles, CA
Background/Purpose: Systemic sclerosis (SSc) is a debilitating disease with few treatment options. Interleukin-6 (IL-6) appears to play a role in SSc pathogenesis (J Rheumatol 1998;25:308;…
Abstract Number: 2151 • 2015 ACR/ARHP Annual Meeting
Inhibition of Myeloid-Associated Gene Expression in Skin Biopsy Samples of Systemic Sclerosis Patients Treated with Tocilizumab
Thierry Sornasse¹, Haiyin Chen¹, Lisa Rice², Giuseppina Stifano², Angelika Jahreis¹, Jeffrey Siegel¹ and Robert Lafyatis², ¹Genentech, South San Francisco, CA, ²Boston University School of Medicine, Boston, MA
Background/Purpose: Systemic sclerosis (SSc) is a progressive, debilitating disease with limited treatment options. IL-6 has been implicated in disease pathogenesis. Tocilizumab (TCZ), an IL-6Rα inhibitor,…
Abstract Number: 874 • 2014 ACR/ARHP Annual Meeting
Safety and Efficacy of Subcutaneous Tocilizumab in Adults with Systemic Sclerosis: Week 24 Data from a Phase 2/3 Trial
Dinesh Khanna¹, Christopher P. Denton², Jacob M. van Laar³, Angelika Jahreis⁴, Sabrina Cheng⁴, Helen Spotswood⁵, Jeffrey Siegel⁴ and Daniel E. Furst on behalf of FaSScinate Clinical Trial in Patients With SS⁶, ¹University of Michigan Health System, Ann Arbor, MI, ²University College London Medical School, London, United Kingdom, ³University Medical Center Utrecht, Utrecht, Netherlands, ⁴Genentech, South San Francisco, CA, ⁵Roche Products Ltd., Welwyn Garden City, United Kingdom, ⁶University of California, Los Angeles, CA
Background/Purpose: Systemic sclerosis (SSc) is a progressive, debilitating disease with limited treatment options. IL-6 has been implicated in disease pathogenesis.1,2 IL-6 receptor inhibition prevented and…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].